Literature DB >> 26768372

Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis.

Jonathan Dyal1, Andrew Akampurira2, Joshua Rhein1, Bozena M Morawski3, Reuben Kiggundu4, Henry W Nabeta4, Abdu K Musubire5, Nathan C Bahr3, Darlisha A Williams1, Tihana Bicanic6, Robert A Larsen7, David B Meya5, David R Boulware8.   

Abstract

Quantitative cerebrospinal fluid (CSF) cultures provide a measure of disease severity in cryptococcal meningitis. The fungal clearance rate by quantitative cultures has become a primary endpoint for phase II clinical trials. This study determined the inter-assay accuracy of three different quantitative culture methodologies. Among 91 participants with meningitis symptoms in Kampala, Uganda, during August-November 2013, 305 CSF samples were prospectively collected from patients at multiple time points during treatment. Samples were simultaneously cultured by three methods: (1) St. George's 100 mcl input volume of CSF with five 1:10 serial dilutions, (2) AIDS Clinical Trials Group (ACTG) method using 1000, 100, 10 mcl input volumes, and two 1:100 dilutions with 100 and 10 mcl input volume per dilution on seven agar plates; and (3) 10 mcl calibrated loop of undiluted and 1:100 diluted CSF (loop). Quantitative culture values did not statistically differ between St. George-ACTG methods (P= .09) but did for St. George-10 mcl loop (P< .001). Repeated measures pairwise correlation between any of the methods was high (r≥0.88). For detecting sterility, the ACTG-method had the highest negative predictive value of 97% (91% St. George, 60% loop), but the ACTG-method had occasional (∼10%) difficulties in quantification due to colony clumping. For CSF clearance rate, St. George-ACTG methods did not differ overall (mean -0.05 ± 0.07 log10CFU/ml/day;P= .14) on a group level; however, individual-level clearance varied. The St. George and ACTG quantitative CSF culture methods produced comparable but not identical results. Quantitative cultures can inform treatment management strategies.
© The Author 2016. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cryptococcus; HIV/AIDS; accuracy; culture; meningitis; methodology

Mesh:

Substances:

Year:  2016        PMID: 26768372      PMCID: PMC4834857          DOI: 10.1093/mmy/myv104

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  17 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.

Authors:  Joseph N Jarvis; Graeme Meintjes; Kevin Rebe; Gertrude Ntombomzi Williams; Tihana Bicanic; Anthony Williams; Charlotte Schutz; Linda-Gail Bekker; Robin Wood; Thomas S Harrison
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

3.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis.

Authors:  P A Robinson; M Bauer; M A Leal; S G Evans; P D Holtom; D A Diamond; J M Leedom; R A Larsen
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

Review 4.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

5.  High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.

Authors:  Tihana Bicanic; Robin Wood; Graeme Meintjes; Kevin Rebe; Annemarie Brouwer; Angela Loyse; Linda-Gail Bekker; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

6.  Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.

Authors:  Angela Loyse; Douglas Wilson; Graeme Meintjes; Joseph N Jarvis; Tihana Bicanic; Leesa Bishop; Kevin Rebe; Anthony Williams; Shabbar Jaffar; Linda-Gail Bekker; Robin Wood; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

7.  Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.

Authors:  Tihana Bicanic; Graeme Meintjes; Robin Wood; Madeleine Hayes; Kevin Rebe; Linda-Gail Bekker; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2007-05-25       Impact factor: 9.079

8.  Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis.

Authors:  Conrad K Muzoora; Taseera Kabanda; Giuseppina Ortu; John Ssentamu; Pasco Hearn; James Mwesigye; Nicky Longley; Joseph N Jarvis; Shabbar Jaffar; Thomas S Harrison
Journal:  J Infect       Date:  2011-11-04       Impact factor: 6.072

9.  Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.

Authors:  Tihana Bicanic; Conrad Muzoora; Annemarie E Brouwer; Graeme Meintjes; Nicky Longley; Kabanda Taseera; Kevin Rebe; Angela Loyse; Joseph Jarvis; Linda-Gail Bekker; Robin Wood; Direk Limmathurotsakul; Wirongrong Chierakul; Kasia Stepniewska; Nicholas J White; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

10.  Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Authors:  Nicky Longley; Conrad Muzoora; Kabanda Taseera; James Mwesigye; Joselyne Rwebembera; Ali Chakera; Emma Wall; Irene Andia; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

View more
  18 in total

1.  Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.

Authors:  Andrew Katende; Gladys Mbwanji; Diana Faini; Amina Nyuri; Aneth Vedastus Kalinjuma; Dorcas Mnzava; Katherine H Hullsiek; Joshua Rhein; Maja Weisser; David B Meya; David R Boulware; Emilio Letang
Journal:  Mycoses       Date:  2019-10-21       Impact factor: 4.377

2.  Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid.

Authors:  Richard Kwizera; Andrew Akampurira; Tadeo K Kandole; Maria S Nabaggala; Darlisha A Williams; Andrew Kambugu; David B Meya; Joshua Rhein; David R Boulware
Journal:  Med Mycol       Date:  2018-07-01       Impact factor: 4.076

3.  Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.

Authors:  Sarah Lofgren; Kathy H Hullsiek; Bozena M Morawski; Henry W Nabeta; Reuben Kiggundu; Kabanda Taseera; Abdu Musubire; Charlotte Schutz; Mahsa Abassi; Nathan C Bahr; Lillian Tugume; Conrad Muzoora; Darlisha A Williams; Melissa A Rolfes; Sruti S Velamakanni; Radha Rajasingham; Graeme Meintjes; Joshua Rhein; David B Meya; David R Boulware
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 4.  Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.

Authors:  Radha Rajasingham; Rachel M Wake; Tafese Beyene; Andrew Katende; Emilio Letang; David R Boulware
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

5.  Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Authors:  Kenneth Ssebambulidde; Ananta S Bangdiwala; Richard Kwizera; Tadeo Kiiza Kandole; Lillian Tugume; Reuben Kiggundu; Edward Mpoza; Edwin Nuwagira; Darlisha A Williams; Sarah M Lofgren; Mahsa Abassi; Abdu K Musubire; Fiona V Cresswell; Joshua Rhein; Conrad Muzoora; Kathy Huppler Hullsiek; David R Boulware; David B Meya
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

6.  Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.

Authors:  Ali A Alhadab; Joshua Rhein; Lillian Tugume; Abdu Musubire; Darlisha A Williams; Mahsa Abassi; Melanie R Nicol; David B Meya; David R Boulware; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-04       Impact factor: 2.745

7.  Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.

Authors:  Joshua Rhein; Kathy Huppler Hullsiek; Lillian Tugume; Edwin Nuwagira; Edward Mpoza; Emily E Evans; Reuben Kiggundu; Katelyn A Pastick; Kenneth Ssebambulidde; Andrew Akampurira; Darlisha A Williams; Ananta S Bangdiwala; Mahsa Abassi; Abdu K Musubire; Melanie R Nicol; Conrad Muzoora; David B Meya; David R Boulware
Journal:  Lancet Infect Dis       Date:  2019-08       Impact factor: 25.071

8.  Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.

Authors:  Matthew F Pullen; Katherine Huppler Hullsiek; Joshua Rhein; Abdu K Musubire; Lillian Tugume; Edwin Nuwagira; Mahsa Abassi; Kenneth Ssebambulidde; Edward Mpoza; Ruben Kiggundu; Andrew Akampurira; Henry W Nabeta; Charlotte Schutz; Emily E Evans; Radha Rajasingham; Caleb P Skipper; Katelyn A Pastick; Darlisha A Williams; Bozena M Morawski; Ananta S Bangdiwala; Graeme Meintjes; Conrad Muzoora; David B Meya; David R Boulware
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

9.  Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis.

Authors:  David R Boulware; Caleb P Skipper; Kiiza Kandole Tadeo; Audrey Nimwesiga; Richard Kwizera; Lucy Apeduno; Emily Martyn; Michael Okirwoth; Elizabeth Nalintya; Radha Rajasingham; Darlisha A Williams; Joshua Rhein; David B Meya; Bosco Kafufu
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

10.  Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Authors:  Joshua Rhein; Bozena M Morawski; Kathy Huppler Hullsiek; Henry W Nabeta; Reuben Kiggundu; Lillian Tugume; Abdu Musubire; Andrew Akampurira; Kyle D Smith; Ali Alhadab; Darlisha A Williams; Mahsa Abassi; Nathan C Bahr; Sruti S Velamakanni; James Fisher; Kirsten Nielsen; David B Meya; David R Boulware
Journal:  Lancet Infect Dis       Date:  2016-03-10       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.